Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-096654
Filing Date
2024-08-14
Accepted
2024-08-14 07:30:23
Documents
71
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q grtx-20240630.htm   iXBRL 10-Q 1264382
2 EX-10.1 grtx-ex10_1.htm EX-10.1 75579
3 EX-31.1 grtx-ex31_1.htm EX-31.1 14666
4 EX-31.2 grtx-ex31_2.htm EX-31.2 16946
5 EX-32.1 grtx-ex32_1.htm EX-32.1 8017
6 EX-32.2 grtx-ex32_2.htm EX-32.2 7198
  Complete submission text file 0000950170-24-096654.txt   5784998

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT grtx-20240630.xsd EX-101.SCH 883722
73 EXTRACTED XBRL INSTANCE DOCUMENT grtx-20240630_htm.xml XML 825034
Mailing Address 45 LIBERTY BLVD. SUITE 230 MALVERN PA 19355
Business Address 45 LIBERTY BLVD. SUITE 230 MALVERN PA 19355 610-725-1500
Galera Therapeutics, Inc. (Filer) CIK: 0001563577 (see all company filings)

EIN.: 461454898 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39114 | Film No.: 241204168
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)